Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCR-177 alone and with pembrolizumab in advanced solid tumors
NCT04348916Phase 1Terminated
- Sponsor
- Oncorus
- Start
- May 2020
- Primary completion
- May 2023
- Modality
- Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 1, open-label trial of ONCR-177 in solid tumor (6 arms), sponsored by Oncorus. Primary endpoints: Percentage of Dose-Limiting Toxicities, Percentage of Adverse Events and 3 more. Started May 2020; status: terminated.
02
Drugs
ONCR-177
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04348916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04348916.